Nanotheranostics for personalized medicine

Tae Hyung Kim, Seulki Lee, Xiaoyuan Chen

Research output: Contribution to journalArticle

Abstract

Nanotheranostics, the integration of diagnostic and therapeutic function in one system using the benefits of nanotechnology, is extremely attractive for personalized medicine. Because treating cancer is not a one-size-fits-all scenario, it requires therapy to be adapted to the patient's specific biomolecules. Personalized and precision medicine (PM) does just that. It identifies biomarkers to gain an understanding of the diagnosis and in turn treating the specific disorder based on the precise diagnosis. By predominantly utilizing the unique properties of nanoparticles to achieve biomarker identification and drug delivery, nanotheranostics can be applied to noninvasively discover and target image biomarkers and further deliver treatment based on the biomarker distribution. This is a large and hopeful role theranostics must fill. However, as described in this expert opinion, current nanotechnology-based theranostics systems engineered for PM applications are not yet sufficient. PM is an ever-growing field that will be a driving force for future discoveries in biomedicine, especially cancer theranostics. In this article, the authors dissect the requirements for successful nanotheranostics-based PM.

Original languageEnglish (US)
Pages (from-to)257-269
Number of pages13
JournalExpert Review of Molecular Diagnostics
Volume13
Issue number3
DOIs
StatePublished - Apr 2013

Fingerprint

Precision Medicine
Biomarkers
Nanotechnology
Expert Testimony
Nanoparticles
Neoplasms
Therapeutics
Pharmaceutical Preparations
Theranostic Nanomedicine

Keywords

  • chemotherapy
  • drug delivery
  • molecular imaging
  • molecular profiling
  • nanotechnology
  • nanotheranostics
  • prodrugs

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

Nanotheranostics for personalized medicine. / Kim, Tae Hyung; Lee, Seulki; Chen, Xiaoyuan.

In: Expert Review of Molecular Diagnostics, Vol. 13, No. 3, 04.2013, p. 257-269.

Research output: Contribution to journalArticle

Kim, Tae Hyung ; Lee, Seulki ; Chen, Xiaoyuan. / Nanotheranostics for personalized medicine. In: Expert Review of Molecular Diagnostics. 2013 ; Vol. 13, No. 3. pp. 257-269.
@article{08dd41418e2a4b85928f48fac102a289,
title = "Nanotheranostics for personalized medicine",
abstract = "Nanotheranostics, the integration of diagnostic and therapeutic function in one system using the benefits of nanotechnology, is extremely attractive for personalized medicine. Because treating cancer is not a one-size-fits-all scenario, it requires therapy to be adapted to the patient's specific biomolecules. Personalized and precision medicine (PM) does just that. It identifies biomarkers to gain an understanding of the diagnosis and in turn treating the specific disorder based on the precise diagnosis. By predominantly utilizing the unique properties of nanoparticles to achieve biomarker identification and drug delivery, nanotheranostics can be applied to noninvasively discover and target image biomarkers and further deliver treatment based on the biomarker distribution. This is a large and hopeful role theranostics must fill. However, as described in this expert opinion, current nanotechnology-based theranostics systems engineered for PM applications are not yet sufficient. PM is an ever-growing field that will be a driving force for future discoveries in biomedicine, especially cancer theranostics. In this article, the authors dissect the requirements for successful nanotheranostics-based PM.",
keywords = "chemotherapy, drug delivery, molecular imaging, molecular profiling, nanotechnology, nanotheranostics, prodrugs",
author = "Kim, {Tae Hyung} and Seulki Lee and Xiaoyuan Chen",
year = "2013",
month = "4",
doi = "10.1586/erm.13.15",
language = "English (US)",
volume = "13",
pages = "257--269",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Nanotheranostics for personalized medicine

AU - Kim, Tae Hyung

AU - Lee, Seulki

AU - Chen, Xiaoyuan

PY - 2013/4

Y1 - 2013/4

N2 - Nanotheranostics, the integration of diagnostic and therapeutic function in one system using the benefits of nanotechnology, is extremely attractive for personalized medicine. Because treating cancer is not a one-size-fits-all scenario, it requires therapy to be adapted to the patient's specific biomolecules. Personalized and precision medicine (PM) does just that. It identifies biomarkers to gain an understanding of the diagnosis and in turn treating the specific disorder based on the precise diagnosis. By predominantly utilizing the unique properties of nanoparticles to achieve biomarker identification and drug delivery, nanotheranostics can be applied to noninvasively discover and target image biomarkers and further deliver treatment based on the biomarker distribution. This is a large and hopeful role theranostics must fill. However, as described in this expert opinion, current nanotechnology-based theranostics systems engineered for PM applications are not yet sufficient. PM is an ever-growing field that will be a driving force for future discoveries in biomedicine, especially cancer theranostics. In this article, the authors dissect the requirements for successful nanotheranostics-based PM.

AB - Nanotheranostics, the integration of diagnostic and therapeutic function in one system using the benefits of nanotechnology, is extremely attractive for personalized medicine. Because treating cancer is not a one-size-fits-all scenario, it requires therapy to be adapted to the patient's specific biomolecules. Personalized and precision medicine (PM) does just that. It identifies biomarkers to gain an understanding of the diagnosis and in turn treating the specific disorder based on the precise diagnosis. By predominantly utilizing the unique properties of nanoparticles to achieve biomarker identification and drug delivery, nanotheranostics can be applied to noninvasively discover and target image biomarkers and further deliver treatment based on the biomarker distribution. This is a large and hopeful role theranostics must fill. However, as described in this expert opinion, current nanotechnology-based theranostics systems engineered for PM applications are not yet sufficient. PM is an ever-growing field that will be a driving force for future discoveries in biomedicine, especially cancer theranostics. In this article, the authors dissect the requirements for successful nanotheranostics-based PM.

KW - chemotherapy

KW - drug delivery

KW - molecular imaging

KW - molecular profiling

KW - nanotechnology

KW - nanotheranostics

KW - prodrugs

UR - http://www.scopus.com/inward/record.url?scp=84876130374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876130374&partnerID=8YFLogxK

U2 - 10.1586/erm.13.15

DO - 10.1586/erm.13.15

M3 - Article

C2 - 23570404

AN - SCOPUS:84876130374

VL - 13

SP - 257

EP - 269

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 3

ER -